An observational study in Rare Diseases, Autism or Autistic Traits and Development Delay, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to participants aged 0 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by University of Missouri-Columbia · Observational
The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.
The current natural history study is being conducted in anticipation of future treatments for patients with confirmed BAGOS. The study is an important avenue of investigation that will increase the understanding of the disorder and lead to important diagnostic and therapeutic advances. Its purpose is to identify demographic, genetic, environmental, and treatment modalities and concomitant medications that correlate with the disease's development and outcomes. This study will use standard scales and questionnaires for the assessment of global development, language, memory, and motor function, and by collecting sleep and seizure diaries. A small blood sample will be collected for whole genome sequencing and proteomic analysis. Brain imaging (MRI) and electroencephalography (EEG) recordings will be collected to identify disease biomarkers. The investigators will also be asking participants to provide a small skin sample for the development of patient specific stem cells which will be used to further understand the impact of Synaptotagmin1 mutations on neurodevelopment and as a potential screen for future therapies.
592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.
This study's planned enrollment of 50 is below the median of 133 across 208 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →University of Missouri-Columbia is the lead sponsor of 365 studies on the registry; 69 are open to participants now.
Of its 43 completed or terminated interventional studies of FDA-regulated products, 29 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Study Population:
This study will comprehensively evaluate the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function and global development, and by collecting sleep and seizure diaries. In addition, genetic and proteomic analysis, EEG recordings and brain MRI will be collected to identify biomarkers that will indicate disease progression or improvements following treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In this study, the primary caregivers/LAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.
Caregivers/LAR will have to meet the following inclusion criteria:
Caregivers/LAR Exclusion Criteria:
Participants will undergo a 5-10 minute non-anesthesia brain MRI in order to evaluate for changes in brain structure. A 20 to 30 minutes 20 channel surface electroencephalography will be performed in the wake and sleep states.
Also known as: Electroencephalography (EEG)
15 milliliters of blood will be collected at the initial visit. Blood samples will be centrifuged, and plasma stored in the University of Missouri Next Gen Precision Health building. Next generation whole genome sequencing and proteomics will be performed on plasma samples. Additional blood will be collected for the DNA biobank.
Also known as: Next Generation Sequencing
A 3 mm skin punch biopsy will be collected for developing induced pluripotential stem cells.
Also known as: iPSP
Collection of relevant medical data (retrospective and prospective)
Collection of demographic data, BAGOS-related medical history, past medical and surgical history, current medication, history of immunizations and family medical history.
Time frame: 24 months
Neurological Assessment Scale
Hammersmith Infant Neurological Examination (HINE) (0-2 years ONLY). Maximum global score of 78. Higher scores indicate a higher degree of neurological performance.
Time frame: 24 months
Clinical Global Impressions Scale - Practitioner
Scales whereby practitioner rates from 1 to 7 the overall improvement/deterioration of the participant affected by BAGOS. One is improved and 7 denotes deterioration.
Time frame: 24 months
Pediatric Evaluation of Disability Inventory
Pediatric Evaluation of Disability Inventory assesses key functional capabilities and performance in children ages 6 months to 7 years.
Time frame: 24 months
Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT)
The PEDI-CAT is a computer adaptive caregiver report which measures Daily Activities, Mobility, Social/Cognitive, and Responsibility. It's designed for use with children and youth with a variety of physical and/or behavioral conditions.
Time frame: 24 months
Gross motor milestones
World Health Organization (WHO) Motor Milestones. Scale of 6 gross motor milestones. Lower scores denote worse motor function.
Time frame: 24 months
Global development assessment scale
Bayley Scales of Infant and Toddler Development - 4 (BSID-4) for Developmental delays. Scale is divided into five domains, which are further divided into subdomains. The first step is to calculate the starting point by beginning with the items that are age appropriate. The starting point is validated if three consecutive items are achieved. If the participant affected by Baker Gordon Syndrome does not achieve three consecutive items in a row at the age-appropriate starting point, the evaluator must go backwards to the lower age-starting point until the participant affected by Baker Gordon Syndrome achieves three items in a row. The assessment stops once five items in a row are not achieved.
Time frame: 24 months
Vineland Adaptive Behavior Scales Third Edition
Vineland Adaptive Behavior Scales Third Edition is the leading instrument for supporting the diagnosis of intellectual and developmental disabilities. Vineland-3 not only aids in diagnosis, but provides valuable information for developing educational and treatment plans
Time frame: 24 months
Aberrant behavior assessment (ABC)
Aberrant Behavior Checklist-Community (ABC-C). This scale comprises 58 items and is divided into five subdomains. The ABC-C is designed on a four-point scale with the lowest score representing less-affected patients while the highest score represents most-affected patients.
Time frame: 24 months
Behavior Assessment System for Children (BASC), 3rd Edition
Behavior Assessment System for Children (BASC), 3rd Edition. A comprehensive set of rating scales and forms, BASC-3 helps participants understand the behaviors and emotions of children and adolescents
Time frame: 24 months
Conners 4th Edition
Conners 4th Edition (Conners 4™) provides a comprehensive assessment of symptoms and impairments associated with ADHD and common co-occurring problems and disorders in children and youth aged 6 to 18 years.
Time frame: 24 months
Motor function assessment
Functional Mobility Scale (FMS). Scale which rates the walking ability in three different walking distances, and these distances will be rated on a 6-point scale. Higher scored denote less impairment.
Time frame: 24 months
Pediatric Sleep Questionnaire (PSQ)
A 22-point questionnaire that assesses the sleep patterns and potential abnormalities in children and their affected quality of life.
Time frame: 24 months
Test of Everyday Attention for Children 2nd Edition (TEA-Ch2)
Test of Everyday Attention for Children Second Edition (TEA-Ch2) uniquely measures separable aspects of attention.
Time frame: 24 months
NEPSY 2nd edition
NEPSY®-II results provide information relating to typical childhood disorders, enabling accurate diagnosis and intervention planning for success in school and at home.
Time frame: 24 months
The Infant/Toddler Sensory Profile
The Infant/Toddler Sensory Profile® was developed to evaluate sensory processing patterns in the very young. The results provide understanding of how sensory processing affects the child's daily functioning performance.
Time frame: 24 months
Mullen Scales of Early Learning
Mullen Scales of Early Learning is a developmentally integrated system that assesses language, motor, and perceptual abilities, measures cognitive ability and motor development quickly and reliability.
Time frame: 24 months
Health economics
Interview with Caregivers
Time frame: 24 months
Clinical trial readiness
Demographic data collection
Time frame: 24 months
Clinical trial readiness
Facilities Preparation
Time frame: 24 months
Laboratory tests
Genomic and proteomic analysis of plasma samples to determine biomarkers of disease progression
Time frame: 24 months
Electroencephalogram activity recordings (EEG)
Electroencephalogram (EEG) to record brain activity of Baker Gordon Syndrome patients over a 2-hour period.
Time frame: 24 months
Brain magnetic resonance imaging (MRI)
Brain magnetic imaging (MRI) to measure the brain grey and white matter volume.
Time frame: 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Missouri-Columbia →